Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

PurposeCD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.MethodsThis retrospective cohort study investigated the use of to...

Full description

Saved in:
Bibliographic Details
Main Authors: Qianyi Zhou, Yuxin An, Xiaomei Zhang, Xia Xiao, Xue Bai, Pengjiang Liu, Yedi Pu, Juanxia Meng, Haibo Zhu, Cuicui Lyu, Huan Zhang, Yu Zhang, Tianle Xie, Haotian Meng, Hairong Lyu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor T (CAR-T) cell
tocilizumab
cytokine release syndrome (CRS)
efficacy and safety
acute B-lymphoblastic leukemia (B-ALL)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530623/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530623/full

Similar Items